MoneyWorks4Me

Epigral informs about press release

12 Nov 2025 Evaluate
Epigral has informed that it enclosed the copies of newspaper advertisement published in Financial Express (English & Gujarati edition) pertaining to Un-Audited Financial Results for the Second Quarter & Half Year ended 30th September, 2025.

The above information is a part of company’s filings submitted to BSE.

Epigral Share Price

1117.40 15.50 (1.41%)
13-Aug-2026 16:59 View Price Chart
Peers
Company Name CMP
SRF 2601.85
BASF India 4132.95
Pidilite Inds. 1686.10
Tata Chemicals 672.20
GNFC 550.10
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: